Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study

BackgroundSafety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these recommendations in routine clinical care.MethodsWe...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Sebastian Hueper, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Stefan Kleinert
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-08-01
Edice:	Frontiers in Immunology
Témata:	rheumatoid arthritis cancer treatment tumor necrosis factor inhibitors interleukin-6 receptor inhibitors oral surveillance
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1445680/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!